Preeclampsia and Circulating Biomarkers
In order to assess circulating biomarkers of cardiovascular risk, we will conduct a 10-year follow-up study comparing 32 exposed (women with a history of pregnancy complicated by preeclampsia) and 32 unexposed (women with a history of uncomplicated pregnancy).
Participants will be recruited from a well-characterised cohort, previously assembled during their pregnancies, at the Department of Obstetrics at Randers Regional Hospital in 2001-2004.
Blood and urine samples, collected during their pregnancies, are stored in a biobank, thus rendering the possibility of longitudinal assessment.
Postpartum CVD Risk in Women With Previous Preeclampsia.
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
- Circulating biomarkers of cardiovascular disease 10 years postpartum. [ Time Frame: 10 years postpartum ] [ Designated as safety issue: No ]
- Markers of arteriosclerosis and atherosclerosis [ Time Frame: 10 years postpartum ] [ Designated as safety issue: No ]
- Circulating biomarkers of cardiovascular disease at baseline pregnancy. [ Time Frame: During pregnancy ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood serum Blood plasma Urine
|Study Start Date:||April 2014|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Women with a history of preeclampsia 10 years ago
Women with a history of uncomplicated pregnancy 10 years ago
Please refer to this study by its ClinicalTrials.gov identifier: NCT02136667
|Randers Regional Hospital||Recruiting|
|Randers, Randers NØ, Denmark, 8930|
|Contact: Martin Christensen, MD 004578422354 email@example.com|
|Principal Investigator: Martin Christensen, MD|
|Study Chair:||Ulla B Knudsen, Professor||Department of Obstetrics and Gynaecology, Aarhus University Hospital|
|Principal Investigator:||Martin Christensen, MD||Clinical Research Unit, Randers Regional Hospital|
|Study Director:||Camilla S Kronborg, MD, PhD||Department of Oncology, Aarhus University Hospital|